SCHEMBL689136

SCHEMBL689136

CCCCCCCCCCC(C)(OCCCCCCCC)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
PLA2G4B P0C869 4/20 0.44
RARB P10826 3/20 0.41
NAAA Q02083 1/20 0.41
CES2 O00748 2/20 0.41
S1PR4 O95977 1/20 0.40
S1PR1 P21453 1/20 0.40
S1PR3 Q99500 1/20 0.40
S1PR5 Q9H228 1/20 0.40
PLA2G4A P47712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477671 1.00 TP53 (0.45) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL12804020 1.00 TP53 (0.45) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL28023365 1.00 TP53 (0.45) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL28023410 1.00 TP53 (0.45) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL17023984 0.94 TP53 (0.42) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL17023982 0.94 TP53 (0.42) TP53TSHRPLA2G4BRARBNAAA
SCHEMBL3284825 0.90 ALDH1A1 (0.40) TP53TSHRPLA2G4BRARB
SCHEMBL3287748 0.89 ALDH1A1 (0.39) TP53TSHRPLA2G4BRARB
SCHEMBL20820038 0.88 SMPD1 (0.40) TP53TSHRPLA2G4BS1PR4S1PR1
SCHEMBL165416 0.87 MEN1 (0.40) TSHRCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US claimed
EP-0793481-B1 COSMETIC COMPOSITION CONTAINING HYDROXY ALKANOATE DERIVATIVES UNILEVER PLC (GB) 2004-06-02 EP claimed
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof MEDIHELPLINE CO., LTD (KR) 2026-05-05 US disclosed
US-20230127213-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF PARK, OK NAM (KR) 2023-04-27 US disclosed
US-20230103514-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-04-06 US disclosed
US-20230100173-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-03-30 US disclosed
EP-4117699-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117698-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117700-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
CN-115297880-A Topical composition comprising extract of crude drug comprising arillus longan for treating or improving skin ulcer, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
CN-115297879-A Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
WO-2007046636-A1 HERBAL COMPOSITION FOR PREVENTING AND IMPROVING BALDNESS KMSI CO., LTD (KR) 2007-04-26 WO disclosed
WO-2007004832-A1 COMPOSITION COMPRISING AN EXTRACT OF CRINUM ASIATICUM LINNE HAVING ANTI-ALLERGIC AND ANTI-INFLAMMATORY ACTIVITY BIOLAND LTD. (KR) 2007-01-11 WO disclosed
WO-2006093793-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF EFFICAS, INC. (US) 2006-09-08 WO disclosed
WO-2006090939-A1 COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING BIOLAND LTD. (KR) 2006-08-31 WO disclosed
WO-2006016728-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS HELIXIR CO., LTD. (KR) 2006-02-16 WO disclosed
EP-1551433-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE Pangenomics Co., Ltd. (KR) 2005-07-13 EP disclosed
WO-2004096171-A1 SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM YEUNGNAM EDUCATIONAL FOUNDATION (KR) 2004-11-11 WO disclosed
WO-2004017982-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE PANGENOMICS CO., LTD (KR) 2004-03-04 WO disclosed
US-20040037909-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease VIROMED CO., LTD. (KR) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof CUTA, VEGFA, MMP8 TP53 2073/4885TSHR 2809/4885PLA2G4B 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.